Tags

Type your tag names separated by a space and hit enter

Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial.
Phytomedicine. 2015 Feb 15; 22(2):290-6.P

Abstract

AIM

Diabetes is a serious metabolic disorder and oxidative stress and inflammation contribute to its pathogenesis and complications. Since Silybum marianum (L.) Gaertn. (silymarin) extract is an antioxidant with anti-inflammatory properties, this randomized clinical trial was conducted to evaluate the effects of silymarin supplementation on oxidative stress indices and hs-CRP in type 2 diabetes mellitus patients.

METHODS

For the present paralleled, randomized, triple-blinded, placebo-controlled clinical trial, 40 type 2 diabetes patients aged 25-50 yr old and on stable medication were recruited from the Iranian Diabetes Society and endocrinology clinics in East Azarbayjan (Tabriz, Iran) and randomly assigned into two groups. Patients in the silymarin treatment group received 140 mg, thrice daily of dried extracts of Silybum marianum (n = 20) and those in the placebo group (n = 20) received identical placebos for 45 days. Data pertaining to height, weight, waist circumference and BMI, as well as food consumption, were collected at base line and at the conclusion of the study. Fasting blood samples were obtained and antioxidant indices and hs-CRP were assessed at baseline, as well as at the end of the trial.

RESULTS

All 40 patients completed the study and did not report any adverse effects or symptoms with the silymarin supplementation. Silymarin supplementation significantly increased superoxide dismutase (SOD), glutathione peroxidase (GPX) activity and total antioxidant capacity (TAC) compared to patients taking the placebo, by 12.85%, 30.32% and 8.43%, respectively (p < 0.05). There was a significant reduction in hs-CRP levels by 26.83% (p < 0.05) in the silymarin group compared to the placebo group. Malondialdehyde (MDA) concentration significantly decreased by 12.01% (p < 0.05) in the silymarin group compared to the baseline.

CONCLUSIONS

Silymarin supplementation improves some antioxidant indices (SOD, GPX and TAC) and decrease hs-CRP levels in T2DM patients.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Ebrahimpour Koujan S
Department of Biochemistry and Diet Therapy, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
Gargari BP
Department of Biochemistry and Diet Therapy, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: bahrampg@yahoo.com.
Mobasseri M
Department of Internal Medicine, Tabriz University of Medical Science, Tabriz, Iran.
Valizadeh H
Research Center for Pharmaceutical Nanotechnology and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Asghari-Jafarabadi M
Department of Epidemiology and Biostatistics, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran.

MeSH

Administration, OralAdultAnti-Inflammatory AgentsAntioxidantsC-Reactive ProteinDiabetes Mellitus, Type 2Dietary SupplementsFemaleGlutathione PeroxidaseHumansInflammationMaleMalondialdehydeMiddle AgedMilk ThistleOxidative StressSilymarinSuperoxide Dismutase

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25765835

Citation

Ebrahimpour Koujan, Soraiya, et al. "Effects of Silybum Marianum (L.) Gaertn. (silymarin) Extract Supplementation On Antioxidant Status and hs-CRP in Patients With Type 2 Diabetes Mellitus: a Randomized, Triple-blind, Placebo-controlled Clinical Trial." Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, vol. 22, no. 2, 2015, pp. 290-6.
Ebrahimpour Koujan S, Gargari BP, Mobasseri M, et al. Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial. Phytomedicine. 2015;22(2):290-6.
Ebrahimpour Koujan, S., Gargari, B. P., Mobasseri, M., Valizadeh, H., & Asghari-Jafarabadi, M. (2015). Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, 22(2), 290-6. https://doi.org/10.1016/j.phymed.2014.12.010
Ebrahimpour Koujan S, et al. Effects of Silybum Marianum (L.) Gaertn. (silymarin) Extract Supplementation On Antioxidant Status and hs-CRP in Patients With Type 2 Diabetes Mellitus: a Randomized, Triple-blind, Placebo-controlled Clinical Trial. Phytomedicine. 2015 Feb 15;22(2):290-6. PubMed PMID: 25765835.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial. AU - Ebrahimpour Koujan,Soraiya, AU - Gargari,Bahram Pourghassem, AU - Mobasseri,Majid, AU - Valizadeh,Hadi, AU - Asghari-Jafarabadi,Mohammad, Y1 - 2015/01/19/ PY - 2014/8/9/received PY - 2014/11/27/revised PY - 2014/12/21/accepted PY - 2015/3/14/entrez PY - 2015/3/15/pubmed PY - 2015/5/15/medline KW - Antioxidants KW - Diabetes mellitus KW - Malondialdehyde KW - Silymarin KW - hs-CRP SP - 290 EP - 6 JF - Phytomedicine : international journal of phytotherapy and phytopharmacology JO - Phytomedicine VL - 22 IS - 2 N2 - AIM: Diabetes is a serious metabolic disorder and oxidative stress and inflammation contribute to its pathogenesis and complications. Since Silybum marianum (L.) Gaertn. (silymarin) extract is an antioxidant with anti-inflammatory properties, this randomized clinical trial was conducted to evaluate the effects of silymarin supplementation on oxidative stress indices and hs-CRP in type 2 diabetes mellitus patients. METHODS: For the present paralleled, randomized, triple-blinded, placebo-controlled clinical trial, 40 type 2 diabetes patients aged 25-50 yr old and on stable medication were recruited from the Iranian Diabetes Society and endocrinology clinics in East Azarbayjan (Tabriz, Iran) and randomly assigned into two groups. Patients in the silymarin treatment group received 140 mg, thrice daily of dried extracts of Silybum marianum (n = 20) and those in the placebo group (n = 20) received identical placebos for 45 days. Data pertaining to height, weight, waist circumference and BMI, as well as food consumption, were collected at base line and at the conclusion of the study. Fasting blood samples were obtained and antioxidant indices and hs-CRP were assessed at baseline, as well as at the end of the trial. RESULTS: All 40 patients completed the study and did not report any adverse effects or symptoms with the silymarin supplementation. Silymarin supplementation significantly increased superoxide dismutase (SOD), glutathione peroxidase (GPX) activity and total antioxidant capacity (TAC) compared to patients taking the placebo, by 12.85%, 30.32% and 8.43%, respectively (p < 0.05). There was a significant reduction in hs-CRP levels by 26.83% (p < 0.05) in the silymarin group compared to the placebo group. Malondialdehyde (MDA) concentration significantly decreased by 12.01% (p < 0.05) in the silymarin group compared to the baseline. CONCLUSIONS: Silymarin supplementation improves some antioxidant indices (SOD, GPX and TAC) and decrease hs-CRP levels in T2DM patients. SN - 1618-095X UR - https://www.unboundmedicine.com/medline/citation/25765835/Effects_of_Silybum_marianum__L___Gaertn___silymarin__extract_supplementation_on_antioxidant_status_and_hs_CRP_in_patients_with_type_2_diabetes_mellitus:_a_randomized_triple_blind_placebo_controlled_clinical_trial_ DB - PRIME DP - Unbound Medicine ER -